MA42776B1 - Composés utiles pour l'inhibition du ror-gamma-t - Google Patents

Composés utiles pour l'inhibition du ror-gamma-t

Info

Publication number
MA42776B1
MA42776B1 MA42776A MA42776A MA42776B1 MA 42776 B1 MA42776 B1 MA 42776B1 MA 42776 A MA42776 A MA 42776A MA 42776 A MA42776 A MA 42776A MA 42776 B1 MA42776 B1 MA 42776B1
Authority
MA
Morocco
Prior art keywords
ror
inhibiting
compounds useful
gamma
pharmaceutical compositions
Prior art date
Application number
MA42776A
Other languages
English (en)
Inventor
John Richard Morphy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42776B1 publication Critical patent/MA42776B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux inhibiteurs du ror-gamma-t et des compositions pharmaceutiques associées.
MA42776A 2015-09-09 2016-09-06 Composés utiles pour l'inhibition du ror-gamma-t MA42776B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562215929P 2015-09-09 2015-09-09
PCT/US2016/050374 WO2017044410A1 (fr) 2015-09-09 2016-09-06 Composés utiles pour l'inhibition du ror-gamma-t
EP16766765.8A EP3347360B1 (fr) 2015-09-09 2016-09-06 Composés utiles pour l'inhibition du ror-gamma-t

Publications (1)

Publication Number Publication Date
MA42776B1 true MA42776B1 (fr) 2020-02-28

Family

ID=56940418

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42776A MA42776B1 (fr) 2015-09-09 2016-09-06 Composés utiles pour l'inhibition du ror-gamma-t

Country Status (41)

Country Link
US (1) US9598431B1 (fr)
EP (1) EP3347360B1 (fr)
JP (1) JP6282789B1 (fr)
KR (1) KR102048780B1 (fr)
CN (1) CN108026112B (fr)
AR (1) AR105821A1 (fr)
AU (1) AU2016318593B2 (fr)
BR (1) BR112018001451B1 (fr)
CA (1) CA2994732C (fr)
CL (1) CL2018000558A1 (fr)
CO (1) CO2018002440A2 (fr)
CR (1) CR20180089A (fr)
CY (1) CY1122287T1 (fr)
DK (1) DK3347360T3 (fr)
DO (1) DOP2018000066A (fr)
EA (1) EA033882B1 (fr)
EC (1) ECSP18018793A (fr)
ES (1) ES2760992T3 (fr)
HK (1) HK1249901B (fr)
HR (1) HRP20192235T1 (fr)
HU (1) HUE047950T2 (fr)
IL (1) IL257202B (fr)
JO (1) JO3638B1 (fr)
LT (1) LT3347360T (fr)
MA (1) MA42776B1 (fr)
MD (1) MD3347360T2 (fr)
MX (1) MX2018002898A (fr)
MY (1) MY195903A (fr)
NZ (1) NZ739518A (fr)
PE (1) PE20181274A1 (fr)
PH (1) PH12018500504A1 (fr)
PL (1) PL3347360T3 (fr)
PT (1) PT3347360T (fr)
RS (1) RS59655B1 (fr)
SI (1) SI3347360T1 (fr)
SV (1) SV2018005647A (fr)
TN (1) TN2018000057A1 (fr)
TW (1) TWI597284B (fr)
UA (1) UA118824C2 (fr)
WO (1) WO2017044410A1 (fr)
ZA (1) ZA201800515B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3589638T3 (da) * 2017-03-02 2021-06-07 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-Gamma-T
SI3589637T1 (sl) * 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
WO2018193297A1 (fr) 2017-04-21 2018-10-25 Cadila Healthcare Limited Nouveaux composés utilisés en tant que modulateurs de ror-gamma
JP2020142989A (ja) * 2017-06-21 2020-09-10 Meiji Seikaファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
US20240051969A1 (en) 2020-12-07 2024-02-15 Diaccurate Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer
WO2023232870A1 (fr) 2022-05-31 2023-12-07 Immunic Ag Modulateurs de rorg/rorgt pour le traitement d'infections virales de type covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (fr) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
JP3790250B2 (ja) * 2004-01-16 2006-06-28 新日鐵化学株式会社 両面導体ポリイミド積層体の連続製造方法
UA107943C2 (en) * 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
SI2501704T1 (sl) * 2009-11-16 2013-11-29 Eli Lilly Company Spojine spiropiperidina kot antagonisti oral-1 receptorja
KR102074089B1 (ko) * 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
RU2014149136A (ru) * 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
KR101742954B1 (ko) * 2012-05-31 2017-06-02 페넥스 파마슈티컬스 아게 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체
WO2014026328A1 (fr) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'indazole et d'indole à substitution 3-cyclohexényle en tant qu'inhibiteurs de rorgammat et leurs utilisations
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
EP3027616B1 (fr) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Composés d'azaindole à titre de modulateurs de rorc
WO2015101928A1 (fr) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Dérivés de thiophène et de thiazole fusionnés utilisés en tant que modulateurs gamma ror

Also Published As

Publication number Publication date
IL257202A (en) 2018-03-29
HK1249901B (zh) 2020-06-19
BR112018001451B1 (pt) 2023-10-10
HUE047950T2 (hu) 2020-05-28
CA2994732A1 (fr) 2017-03-16
AU2016318593A1 (en) 2018-02-15
EP3347360A1 (fr) 2018-07-18
MD3347360T2 (ro) 2020-03-31
JP2018507203A (ja) 2018-03-15
CR20180089A (es) 2018-02-27
MX2018002898A (es) 2018-06-18
NZ739518A (en) 2019-06-28
LT3347360T (lt) 2020-01-27
SV2018005647A (es) 2018-07-23
PT3347360T (pt) 2020-01-07
HRP20192235T1 (hr) 2020-03-20
IL257202B (en) 2020-02-27
MY195903A (en) 2023-02-27
TW201722964A (zh) 2017-07-01
CA2994732C (fr) 2020-06-30
CL2018000558A1 (es) 2018-08-10
KR20180031777A (ko) 2018-03-28
AR105821A1 (es) 2017-11-15
PL3347360T3 (pl) 2020-04-30
EA033882B1 (ru) 2019-12-05
WO2017044410A1 (fr) 2017-03-16
ZA201800515B (en) 2019-06-26
SI3347360T1 (sl) 2019-12-31
EA201890364A1 (ru) 2018-08-31
JP6282789B1 (ja) 2018-02-21
UA118824C2 (uk) 2019-03-11
ES2760992T3 (es) 2020-05-18
CO2018002440A2 (es) 2018-07-10
TN2018000057A1 (en) 2019-07-08
US9598431B1 (en) 2017-03-21
US20170066781A1 (en) 2017-03-09
PE20181274A1 (es) 2018-08-03
CN108026112A (zh) 2018-05-11
JO3638B1 (ar) 2020-08-27
EP3347360B1 (fr) 2019-10-23
CY1122287T1 (el) 2020-11-25
AU2016318593B2 (en) 2018-10-04
TWI597284B (zh) 2017-09-01
DK3347360T3 (da) 2020-01-02
PH12018500504A1 (en) 2018-09-24
RS59655B1 (sr) 2020-01-31
CN108026112B (zh) 2020-04-10
DOP2018000066A (es) 2018-03-30
BR112018001451A2 (pt) 2018-09-11
ECSP18018793A (es) 2018-04-30
KR102048780B1 (ko) 2019-11-27

Similar Documents

Publication Publication Date Title
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
PH12017501888A1 (en) Bromodomain inhibitor
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MA41013A (fr) Compositions comprenant des souches bactériennes
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
CU20180134A7 (es) Derivados de piridiniltriazol sustituidos con amida útiles para tratar enfermedades renales y cardiovasculares
PH12016500722A1 (en) Bromodomain inhibitors
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA39025B1 (fr) Pipéridyl-éthyl-pyrimidine substituée utilisée comme inhibiteur de la ghréline o-acyl transférase
TN2017000213A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
EA201792093A1 (ru) 2-тиопиримидиноны